MedTrace Logo

Safety,Tolerability, and Pharmacokinetic of KPCXM18 for Injection

NCT04629287 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2020-11-19

No results posted yet for this study

Summary

to assess the safety,Tolerability, and pharmacokinetic of KPCXM18 for injection in healthy subjects

Conditions

  • Healthy

Interventions

DRUG

KPCXM18

KPCXM18,blind,freeze-dried powder,ascending doses，Intravenous route

DRUG

Placebo

Placebo,blind,freeze-dried powder,ascending doses，Intravenous route

Sponsors & Collaborators

  • Kunming Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • yuhong huang, Prof. · Second Affiliated Hospital of Tianjin University of TCM

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-30
Primary Completion
2021-12-31
Completion
2022-02-28

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04629287 on ClinicalTrials.gov